비교리스트

 카트 문의
시장보고서
상품코드
1493177

임상의사결정지원시스템 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 제공 형태별, 구성요소별, 지역별, 부문별 예측(2024-2030년)

Clinical Decision Support Systems Market Size, Share & Trends Analysis Report By Product (Standalone CDSS, Integrated EHR With CDSS), By Application (Drug-Drug Interactions), By Delivery Mode, By Component, By Region, And Segment Forecasts, 2024 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 135 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

임상의사결정지원시스템 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 임상의사결정지원시스템 세계 시장 규모는 2030년까지 107억 1,000만 달러에 달할 것으로 예상되며, 2024년부터 2030년까지 연평균 10.79% 성장할 것으로 예상됩니다.

임상의사결정지원시스템(CDSS)의 도입과 통합을 촉진하기 위한 정부 이니셔티브는 병원과 의료 기관에 이러한 솔루션을 도입할 수 있는 인센티브를 제공함으로써 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 미국 보건복지부(HHS)는 2023년 4월 임상 의사결정 지원 도구의 사용을 확대하기 위해 인증 프로그램 규정을 개정했습니다. 또한, AI 및 클라우드 기반 CDSS 기술의 발전은 시장 확대를 가속화할 것으로 예상되며, CDSS 플랫폼 및 데이터베이스 관리를 강화하기 위한 클라우드 기반 컴퓨팅의 도입도 예측 기간 동안 시장 성장에 긍정적인 영향을 미칠 것으로 예상됩니다.

COVID-19 팬데믹 기간 동안 다양한 정부 기관과 지역 단체가 의료 인프라를 강화하기 위한 노력을 시작했습니다. 이러한 노력은 주 당국의 일선 진료소 설치부터 의료 전문가 자원봉사자 패널 동원, 민간 원격의료 플랫폼 구축에 이르기까지 다양합니다. 임상 판단 지원 시스템(CDSS)은 의사가 진료 시점에 정보에 입각한 판단을 내릴 수 있도록 지원함으로써 이 위기 상황에서 필수적인 역할을 수행했습니다.

그 결과, 시장 진입 기업들은 이 기회를 활용하여 도전과제를 해결하고 일선 의료 서비스 제공자들을 지원했습니다. 예를 들어, 2022년 5월, 아테나헬스(athenahealth, Inc.)의 자회사인 epocrates는 COVID-19 팬데믹으로 인한 문제를 더 잘 관리하기 위해 임상 의사결정 지원 도구를 강화했습니다.

또한, 여러 기업들이 임상의사결정지원시스템(CDSS) 제공을 강화하는 전략을 적극적으로 실행하며 시장에서의 입지를 다지고 있습니다. 예를 들어, 2024년 2월 엘스비어 헬스(Elsevier Health)는 의료 분야 맞춤형 AI 솔루션 제공업체인 오픈에비던스(OpenEvidence)와 협력하여 미국에서 ClinicalKey AI를 출시했습니다. 이 협업은 고급 의료 컨텐츠와 생성형 인공지능(AI)을 통합하여 임상의의 환자 진료 상호작용을 지원합니다.

임상의사결정지원시스템 시장 보고서 하이라이트

  • 제품별로는 독립형 CDSS 부문이 저렴한 비용으로 인해 2023년 30.85%의 가장 큰 매출 점유율을 차지하며 시장을 주도했습니다. 이 부문은 2030년까지 전체 시장의 약 31.0%를 차지할 것으로 추정됩니다.
  • 용도별로는 약물 알레르기 경보 분야가 알레르기 부담이 증가함에 따라 2023년 25.83%의 가장 큰 매출 점유율로 시장을 주도했습니다.
  • 제공 형태별로는 온프레미스 부문이 2023년 42.35%로 가장 큰 매출 점유율을 차지하며 시장을 주도했습니다.
  • 구성요소별로는 서비스 분야가 2023년 42.49%의 가장 큰 매출 점유율로 시장을 주도했습니다.
  • 북미가 2023년 43.76%의 매출 점유율로 시장을 장악했습니다. 이는 시장 기업의 강력한 존재감과 임상 의사 결정 지원 도구의 효율적인 사용을 촉진하기 위한 정부의 노력이 증가하고 있기 때문입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 임상의사결정지원시스템 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상부 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 임상의사결정지원시스템 시장 분석 툴
    • 업계 분석 - Porter's Five Forces 분석
    • PESTEL 분석
  • COVID-19의 영향

제4장 임상의사결정지원시스템 시장 : 제품 추정·동향 분석

  • 제품 시장 점유율, 2023년 및 2030년
  • 부문 대시보드
  • 세계 임상의사결정지원시스템 시장, 제품별 전망
  • 독립형 CDSS
  • CDSS와 통합한 CPOE
  • CDSS와 통합한 EHR
  • CPOE와 HER을 통합한 CDSS

제5장 임상의사결정지원시스템 시장 : 용도 추정·동향 분석

  • 용도 시장 점유율, 2023년 및 2030년
  • 부문 대시보드
  • 세계의 임상의사결정지원시스템 시장, 용도별 전망
  • 약물 상호작용
  • 약물 알레르기 경고
  • 임상상 주의
  • 임상 가이드라인
  • 약제 투여 서포트
  • 기타

제6장 임상의사결정지원시스템 시장 : 제공 모드 추정·동향 분석

  • 제공 모드 시장 점유율, 2023년과 2030년
  • 부문 대시보드
  • 세계의 임상의사결정지원시스템 시장, 제공 모드별 전망
  • 웹 기반 시스템
  • 클라우드 기반 시스템
  • 온프레미스 시스템

제7장 임상의사결정지원시스템 시장 : 컴포넌트 추정·동향 분석

  • 컴포넌트 시장 점유율, 2023년 및 2030년
  • 부문 대시보드
  • 세계의 임상의사결정지원시스템 시장, 컴포넌트별 전망
  • 하드웨어
  • 소프트웨어
  • 서비스

제8장 임상의사결정지원시스템 시장 : 지역 추정·동향 분석, 유형별, 용도별, 제공 모드별, 컴포넌트별

  • 지역별 시장 점유율 분석, 2023년 및 2030년
  • 지역 시장 대시보드
  • 세계 지역 시장 현황
  • 시장 규모와 예측 동향 분석, 2018-2030년
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제9장 경쟁 상황

  • 주요 시장 진출 기업에 의한 최근의 동향과 영향 분석
  • 기업/경쟁 분류
    • 이노베이터
  • 벤더 상황
    • 주요 유통업체 및 채널 파트너 리스트
    • 주요 고객
    • 주요 기업의 시장 점유율 분석, 2023년
    • McKesson Corporation
    • Oracle(Cerner Corporation)
    • Siemens Healthineers GmbH
    • Allscripts Healthcare, LLC
    • athenahealth, Inc.
    • NextGen Healthcare Inc.
    • Koninklijke Philips NV
    • IBM
    • Agfa-Gevaert Group
    • Wolters Kluwer NV
ksm 24.06.18

Clinical Decision Support Systems Market Growth & Trends:

The global clinical decision support systems market size is anticipated to reach USD 10.71 billion by 2030 and is projected to grow at a CAGR of 10.79% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government initiatives aimed at promoting the adoption and integration of Clinical Decision Support Systems (CDSS) are expected to drive market growth by incentivizing hospitals and healthcare organizations to deploy such solutions. For example, in April 2023, the U.S. Department of Health and Human Services (HHS) revised certification program rules to encourage greater utilization of clinical decision support tools. Furthermore, advancements in AI and cloud-based CDSS technologies are projected to accelerate market expansion. The implementation of cloud-based computing to enhance CDSS platforms and database management is also anticipated to positively influence market growth in the forecast period.

During the COVID-19 pandemic, various government and community organizations initiated efforts to bolster the healthcare infrastructure. These initiatives ranged from setting up frontline clinics by state authorities to mobilizing volunteer panels of medical professionals and deploying private telemedicine platforms. Clinical Decision Support Systems (CDSS) proved indispensable during this crisis, assisting physicians in making informed decisions at the point of care.

Consequently, market participants capitalized on this opportunity to address challenges and support frontline healthcare providers. For example, in May 2022, epocrates, a subsidiary of athenahealth, Inc., enhanced its clinical decision support tools to better manage the challenges posed by the COVID-19 pandemic.

Furthermore, several companies are actively implementing strategies to enhance their clinical decision support systems (CDSS) offerings, consolidating their position in the market. For example, in February 2024, Elsevier Health collaborated with OpenEvidence, a prominent provider of AI solutions customized for the medical domain, to launch ClinicalKey AI in the U.S. This collaboration involved integrating advanced medical content with generative artificial intelligence (AI) to assist clinicians in patient-care interactions.

Clinical Decision Support Systems Market Report Highlights:

  • Based on product, the standalone CDSS segment led the market with the largest revenue share of 30.85% in 2023, owing to its low cost. The segment is estimated to hold approximately 31.0% of the overall market by 2030
  • Based on application, the drug allergy alerts segment led the market with the largest revenue share of 25.83% in 2023, owing to the rising burden of allergies
  • Based on delivery mode, the on-premises segment held the market with the largest revenue share of 42.35% in 2023, owing to its high adoption rate by healthcare organizations
  • Based on component, the services segment led the market with the largest revenue share of 42.49% in 2023, owing to high frequency of updating software and other maintenance services
  • North America dominated the market with the revenue share of 43.76% in 2023, due to strong presence of market player and increasing government initiatives to promote efficient usage of clinical decision support tools

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Application
    • 1.1.3. Delivery Mode
    • 1.1.4. Component
    • 1.1.5. Regional scope
    • 1.1.6. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Clinical Decision Support Systems Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Clinical Decision Support Systems Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic Landscape
  • 3.4. COVID-19 Impact

Chapter 4. Clinical Decision Support Systems Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Clinical Decision Support Systems Market by Product Outlook
  • 4.4. Standalone CDSS
    • 4.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 4.5. Integrated CPOE with CDSS
    • 4.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 4.6. Integrated EHR with CDSS
    • 4.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 4.7. Integrated CDSS with CPOE and HER
    • 4.7.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 5. Clinical Decision Support Systems Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Clinical Decision Support Systems Market, by Application Outlook
  • 5.4. Drug-Drug Interactions
    • 5.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 5.5. Drug Allergy Alerts
    • 5.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 5.6. Clinical Reminders
    • 5.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 5.7. Clinical Guidelines
    • 5.7.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 5.8. Drug Dosing Support
    • 5.8.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 6. Clinical Decision Support Systems Market: Delivery Mode Estimates & Trend Analysis

  • 6.1. Delivery Modes Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Clinical Decision Support Systems Market, by Delivery Modes Outlook
  • 6.4. Web-Based Systems
    • 6.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 6.5. Cloud-Based Systems
    • 6.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 6.6. On-Premise Systems
    • 6.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 7. Clinical Decision Support Systems Market: Component Estimates & Trend Analysis

  • 7.1. Component Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Clinical Decision Support Systems Market, by Component Outlook
  • 7.4. Hardware
    • 7.4.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 7.5. Software
    • 7.5.1. Market estimates and forecast, 2018 to 2030 (USD Million)
  • 7.6. Services
    • 7.6.1. Market estimates and forecast, 2018 to 2030 (USD Million)

Chapter 8. Clinical Decision Support Systems Market: Regional Estimates & Trend Analysis, By Type, By Application, By Delivery Mode, By Component

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key Country Dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts,, 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts,, 2018 to 2030 (USD Million)
    • 8.7.6. Singapore
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Singapore market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.2. Mexico
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
    • 9.2.1. Innovators
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. McKesson Corporation
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Oracle (Cerner Corporation)
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Siemens Healthineers GmbH
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Allscripts Healthcare, LLC
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. athenahealth, Inc.
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. NextGen Healthcare Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Koninklijke Philips N.V.
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. IBM
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Agfa-Gevaert Group
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Wolters Kluwer N.V.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제